Published in Am J Psychiatry on January 01, 2007
Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl) (2008) 2.64
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
Is subjective duration a signature of coding efficiency? Philos Trans R Soc Lond B Biol Sci (2009) 1.62
Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull (2008) 1.61
Diagnostic validity of sensory over-responsivity: a review of the literature and case reports. J Autism Dev Disord (2007) 1.38
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry (2011) 1.22
Endophenotypes in schizophrenia: a selective review. Schizophr Res (2009) 1.19
Research review: Cholinergic mechanisms, early brain development, and risk for schizophrenia. J Child Psychol Psychiatry (2009) 1.06
Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry (2007) 1.06
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res (2007) 0.98
Brief subjective durations contract with repetition. J Vis (2008) 0.94
Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res (2014) 0.94
Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology (2007) 0.91
Smooth pursuit eye movement, prepulse inhibition, and auditory paired stimuli processing endophenotypes across the schizophrenia-bipolar disorder psychosis dimension. Schizophr Bull (2013) 0.86
Removal of GABA(A) receptor γ2 subunits from parvalbumin neurons causes wide-ranging behavioral alterations. PLoS One (2011) 0.84
Gsx1 expression defines neurons required for prepulse inhibition. Mol Psychiatry (2014) 0.81
Interaction between the effects of corticotropin-releasing factor and prepulse parameters on prepulse inhibition in two inbred rat strains and the F1 generation of a cross between them. Behav Brain Res (2009) 0.81
Mismatch negativity and low frequency oscillations in schizophrenia families. Clin Neurophysiol (2012) 0.81
Prepulse inhibition of change-related P50m no correlation with P50m gating. Springerplus (2013) 0.78
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull (2004) 7.58
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry (2008) 3.13
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull (2009) 2.61
Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05
Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. Arch Gen Psychiatry (2009) 2.03
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.76
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry (2007) 1.73
A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci U S A (2010) 1.70
Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia. Schizophr Res (2005) 1.69
Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res (2004) 1.65
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia. Am J Psychiatry (2002) 1.62
Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia. Clin Neurophysiol (2013) 1.52
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology (2009) 1.41
Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull (2006) 1.39
Galantamine-induced QTc prolongation. J Clin Psychiatry (2006) 1.38
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry (2002) 1.36
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry (2004) 1.35
Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am J Psychiatry (2013) 1.35
Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull (2005) 1.34
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status. Schizophr Res (2004) 1.33
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull (2006) 1.30
No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology (2005) 1.29
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology (2009) 1.28
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
The speed of visual attention in schizophrenia: electrophysiological and behavioral evidence. Schizophr Res (2006) 1.26
Genetics and intermediate phenotypes of the schizophrenia--bipolar disorder boundary. Neurosci Biobehav Rev (2009) 1.26
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Impaired response selection in schizophrenia: evidence from the P3 wave and the lateralized readiness potential. Psychophysiology (2009) 1.23
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry (2011) 1.22
Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (2010) 1.19
Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2003) 1.18
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res (2013) 1.16
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry (2002) 1.16
Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr Res (2006) 1.12
Working memory for visual features and conjunctions in schizophrenia. J Abnorm Psychol (2003) 1.11
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry (2004) 1.09
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res (2013) 1.08
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res (2011) 1.08
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials. Schizophr Res (2007) 1.07
Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry (2007) 1.06
Specific motion processing pathway deficit during eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.04
Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport (2004) 1.04
A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol (2012) 1.04
Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull (2003) 1.04
Lessons to take home from CATIE. Psychiatr Serv (2008) 1.04
Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) (2004) 1.03
White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2008) 1.02
Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord (2007) 1.00
Components of the smooth pursuit function in deficit and nondeficit schizophrenia. Schizophr Res (2003) 0.99
Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology (2003) 0.99
Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans. Psychophysiology (2007) 0.99
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry (2004) 0.98
Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch Gen Psychiatry (2006) 0.98
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull (2011) 0.97
Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull (2006) 0.97
A shared low-frequency oscillatory rhythm abnormality in resting and sensory gating in schizophrenia. Clin Neurophysiol (2011) 0.97
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry (2003) 0.96
Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry (2002) 0.96
Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. Schizophr Bull (2013) 0.94
The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry (2002) 0.94
Refining the predictive pursuit endophenotype in schizophrenia. Biol Psychiatry (2007) 0.93
The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull (2002) 0.92
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry (2009) 0.92